Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial

Öztürk, Berrîn; Egehan, Îbrahîm; Atavci, S; Kitapçı, Mehmet

doi:10.1016/s0360-3016(03)01444-5

Cited by 144 publications

(80 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For examples, glutamine, a non-essential amino acid was widely studied for its potential protective effect on mucositis, dermatitis and oespahagitis [114][115][116][117] ; pentoxifyline, a methyl xanthine derivative, decreased the risk of radiation toxicity in lung [118] ; benzydamine could prevent and treat oral mucositis [119] ; and sulfasalazine was evaluated for its effects on radiotherapy-induced enteritis [120] . To date, there are still a limited number of chemical RAs clinically used to minimize the severity and duration of toxicities associated with radiotherapy.…”

Section: Ra Its Categoris and Mechanisms Of Functionmentioning

confidence: 99%

Research and Development of Radioprotective Agents: A Mini-Review

Saaya

Katsube

Xie

et al. 2017

International Journal of Radiology

View full text Add to dashboard Cite

The research and development (R&D) of radioprotective agents (RAs) have been conducting since seven decades ago, and the safety and protection against undesirable effects of ionizing radiation (IR) has become an important issue especially for the benefit of patients receiving the radiotherapy, in addition to the applications in nuclear industry, military, outer space exploration and accidental exposures. Although the technology advancement makes the radiotherapy a promising better treatment by maximizing the effect of IR to the cancer cells, there are still needs for improvement in minimizing the toxicity to the normal cells. Aiming at providing the new researchers in the radiation protection field with an overall view for R&D of the RAs, this mini-review elucidates in brief a general understanding of the IR and its effects on the cell, the concepts of radiotherapy and therapeutic ratio, the categories of RAs and their mechanisms, and discusses on the strategies and challenge for R&D of the RAs.

show abstract

Section: Ra Its Categoris and Mechanisms Of Functionmentioning

confidence: 99%

Research and Development of Radioprotective Agents: A Mini-Review

Saaya

Katsube

Xie

et al. 2017

International Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…Damage inside or outside radiation field xanthine derivative that has shown potential to reduce radiation toxicity and has been reported to reduce pneumonitis when given during radiotherapy in patients [134]. It has also been shown to maintain perfusion in rats at late times following irradiation but had little effect on pneumonitis or fibrosis [135,136].…”

Section: Rosmentioning

confidence: 99%

Effects of genistein following fractionated lung irradiation in mice

Para¹,

Bezjak²,

Yeung³

et al. 2009

Radiotherapy and Oncology

View full text Add to dashboard Cite

Radiation therapy for lung cancer and cancers of the upper thorax is limited by side effects to normal tissue of the lung. An understanding of mechanisms leading to radiation induced lung damage is essential to developing protective agents. In this thesis an anti-oxidant and anti-inflammatory agent Genistein was investigated for its potential to affect DNA damage, tissue inflammation, functional deficits and survival. We hypothesized that chronic oxidative stress and the subsequent inflammatory response play a key role in the development of major lung complications, radiation pneumonitis and fibrosis. If side effects of radiation could be reduced, then larger doses could be delivered to the tumor with a better chance of eradicating the disease.ii Acknowledgements

show abstract

“…Gothard et al have shown significant ecancer 2008, 2:81 improvements in Lent-Soma scores for genito-urinary dysfunction and proctitis with this combination [15]. This combination has also been studied in osteoradionecrosis [16], and pentoxifylline has been shown to be of benefit in radiationinduced trismus [17] and lung toxicity in patients with breast and lung cancer [18].…”

Section: Discussionmentioning

confidence: 98%

A randomised prospective study of extended tocopherol and pentoxifylline therapy, in addition to carbogen, in the treatment of radiation late effects

Brennan¹,

Salib²,

O'Shea³

et al. 2008

ecancer

View full text Add to dashboard Cite

Purpose: pentoxifylline (PTX) and tocopherol (vitamin E) are antioxidants previously shown to be useful in combination in the treatment of late radiation induced toxicity. The purpose of this study was to investigate the benefit of combination therapy with carbogen pentoxifylline and tocopherol in the mitigation of late radiation effects. As the optimal duration of PTX and tocopherol treatment has not been fully established, we studied short versus extended treatment duration.Methods: we conducted a phase II prospective randomized study of short versus prolonged treatment with pentoxifylline (800 mg) and tocopherol (1000 IU) orally once daily in patients with grade three toxicity post-radical radiotherapy. In addition, all 18 patients received inhaled carbogen (95% O + 5% CO 2 ) over 90 minutes, five days/week, for three weeks. The primary end point was improved in maximum Lent-Soma toxicity scores.Results: maximum Lent-Soma scores improved in six of the 18 patients (response rate 33%). The proportion of patients responding to treatment in the prolonged treatment arm B was more than double than in the shorter arm A, but this did not reach statistical significance (p=0.321). Two patients who had prolonged treatment (arm B) had complete resolution of their symptoms, which was maintained at two and three year follow-ups.Conclusions: we recommend prolonged treatment for 12 months, with PTX and tocopherol in combination with carbogen therapy, in the management of late radiation effects.

show abstract

Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial

Cited by 144 publications

References 37 publications

Research and Development of Radioprotective Agents: A Mini-Review

Research and Development of Radioprotective Agents: A Mini-Review

Effects of genistein following fractionated lung irradiation in mice

A randomised prospective study of extended tocopherol and pentoxifylline therapy, in addition to carbogen, in the treatment of radiation late effects

Contact Info

Product

Resources

About